Hematologic Oncology
Latest News
Advertisement
Latest Videos
CME Content
Advertisement
More News
Polycythemia Vera: Ruxolitinib Trial Data
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
Polycythemia Vera: Switching Therapy
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
Treatment Options for High-Risk Polycythemia Vera
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
Management of Low-Risk Polycythemia Vera
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
Polycythemia Vera: Monitoring Patients
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
Polycythemia Vera: Risk Assessment
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
Polycythemia Vera: Prognostic Markers
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
Polycythemia Vera: Bone Marrow Biopsies
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
Polycythemia Vera: Diagnostic Work-up
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
Characterization of Myeloproliferative Neoplasms
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
Andrew Yee, MD, discusses the utility of isatuximab-irfc in relapsed/refractory multiple myeloma.
The FDA has lifted a partial clinical hold that was placed on the phase 2 clinical trial of camidanlumab tesirine in patients with relapsed/refractory Hodgkin lymphoma.
Courtney D. DiNardo, MD, MSCE, discusses the results of the study evaluating the combination of azacitidine plus venetoclax in elderly patients with AML.
John P. Leonard, MD, discusses the FDA approval of tazemetostat in patients with follicular lymphoma.
Patient recruitment has been discontinued to an interim futility analysis of a phase 3 trial evaluating pracinostat in combination with azacitidine in patients with acute myeloid leukemia demonstrated that it is unlikely to meet the primary end point of overall survival compared with a control arm.
Jia Ruan, MD, PhD, discusses the utility of molecular profiling in mantle cell lymphoma.
A new drug application has been submitted to the FDA seeking an accelerated approval for melphalan flufenamide in combination with dexamethasone in the treatment of adult patients with triple-refractory multiple myeloma.
Nikhil C. Munshi, MD, discusses the role of CAR T-cell therapy in relapsed/refractory multiple myeloma.
Shaji K. Kumar, MD, discusses stem cell mobilization multiple myeloma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep Plus Bevacizumab/FOLFIRI in Second-Line KRAS-Mutant mCRC
2
FDA Grants Priority Review to Frontline Dato-DXd for Metastatic TNBC Ineligible for Immunotherapy
3
On World Cancer Day, Northwell Highlights a Blueprint for Consistent, System-Wide Cancer Care
4
Leveraging AI for Optimal Clinical Trial Design in Oncology
5